Skip to main content
. 2022 Jan 6;12:788159. doi: 10.3389/fneur.2021.788159

Figure 5.

Figure 5

Proportion of patients who achieved controlled chronic migraine (<15 headache days/month) status on combination treatment with onabotulinumtoxinA and CGRP mAb. CGRP, calcitonin gene-related peptide; CI, confidence interval; mAb, monoclonal antibody; onabotA, onabotulinumtoxinA. *Indicates statistical significance (i.e., 95% CI does not include zero).